Product Logos

HyperRAB S/D Rabies Immune Globulin (Human) HyperTET S/D Tetanus Immune Globulin (Human) HyperRHO S/D Rho(D) Immune Globulin (Human) HyperHEP B S/D Hepatitis B Immune Globulin (Human) GamaSTAN S/D Immune Globulin (Human) HyperRAB S/D Prescribing Information HyperTET S/D Prescribing Information HyperRHO S/D Prescribing Information HyperHEP B S/D Prescribing Information GamaSTAN S/D Prescribing Information

When there’s a critical, potentially life-threatening immune challenge—Choose Hypermunes™ for a rapid, acute response

Hypermunes are specific immunoglobulins that provide rapid immune coverage in potentially life-threatening situations.

Active vs Passive Immunity

Active Immunity is the stimulation of the immune system to produce antigen-specific humoral (antibody) and cellular immunity. This immunity is usually life-long, but may take weeks to build efficacy. In times of urgency, when the need is acute, passive immunity is required.

Passive Immunity is the transfer of antibody produced by one human or other animal to another. This protection is temporary. Passive immunity, provided by the Hypermunes product line, gives you the immediate protection that is needed when faced with potentially life-threatening situations.

Imminent Threat

Vaccines can take weeks to build efficacy, which can protect for years. Hypermunes provide immediate protection, which allows the vaccine the time needed to establish active immunity in high-risk situations.1

Immediate Protection

Hypermunes contain high titers of antibodies for postexposure prophylaxis, providing rapid immune protection.2

A vaccine alone may not be enough for your patients faced with critical situations. Make sure you're prepared. For more information on a specific Hypermune, click above.

References:

  1. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine. 2007;57:552-556.

  2. Centers for Disease Control and Prevention. Principles of vaccination. http://cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf. Accessed September 17, 2009.

HyperRAB S/D IMPORTANT SAFETY INFORMATION

HyperRAB S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

The attending physician who wishes to administer HyperRAB S/D to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA. As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

Soreness at the site of injection and mild temperature elevations may be observed at times. Sensitization to repeated injections has occurred occasionally in immunoglobulin-deficient patients. Angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock have rarely been reported after intramuscular injection, so that a causal relationship between immunoglobulin and these reactions is not clear.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Rabies Immune Globulin (human) administration.

HyperRAB S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

HyperTET S/D IMPORTANT SAFETY INFORMATION

HyperTET S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET S/D should be given only if the expected benefits outweigh the risks.

Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin, there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Tetanus Immune Globulin (Human) administration.

HyperTET S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

HyperRHO S/D Full Dose and Mini-Dose IMPORTANT SAFETY INFORMATION

WARNINGS

HyperRHO S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses that can cause disease.

PLEASE SEE WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS IN THE PRESCRIBING INFORMATION. NEVER ADMINISTER HyperRHO S/D FULL DOSE INTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. NEVER ADMINISTER TO THE NEONATE.

NEVER ADMINISTER HyperRHO S/D MINI-DOSE INTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. ADMINISTER ONLY TO WOMEN POSTABORTION OR POSTMISCARRIAGE OF UP TO 12 WEEKS' GESTATION. NEVER ADMINISTER TO THE NEONATE.

RhO (D) Immune Globulin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. The attending physician who wishes to administer RhO (D) Immune Globulin (Human) to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA. As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

PRECAUTIONS

HyperRHO S/D FULL DOSE AND HyperRHO S/D MINI-DOSE:

A large fetomaternal hemorrhage late in pregnancy or following delivery may cause a weak mixed field positive DU test result. If there is any doubt about the mother’s Rh type, she should be given RhO (D) Immune Globulin (Human). A screening test to detect fetal red blood cells may be helpful in such cases. If more than 15 mL of D-positive red blood cells are present in the mother’s circulation, more than a single dose of HyperRHO S/D Full Dose is required. Failure to recognize this may result in the administration of an inadequate dose.

HyperRHO S/D FULL DOSE:

Although systemic reactions to human immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic symptoms.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after RhO (D) Immune Globulin (Human) administration.

Should be given in pregnant women only if clearly needed because animal reproduction studies have not been conducted.

Safety and efficacy in pediatric patients have not been established.

ADVERSE REACTIONS

HyperRHO S/D FULL DOSE:

Elevated bilirubin levels have been reported in some individuals receiving multiple doses of RhO (D) Immune Globulin (Human) following mismatched transfusions. This is believed to be due to a relatively rapid rate of foreign red cell destruction.

HyperRHO S/D FULL DOSE AND HyperRHO S/D MINI-DOSE:

Reactions to RhO (D) Immune Globulin (Human) are infrequent in RhO (D)-negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human immunoglobulin is extremely rare, it has occurred.

HyperRHO S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

HyperHEP B S/D IMPORTANT SAFETY INFORMATION

HyperHEP B S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Epinephrine should be available.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Hepatitis B Immune Globulin (Human) should be given only if the expected benefits outweigh the risks.

Local pain and tenderness at the injection site, urticaria, and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immunoglobulin preparations.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Hepatitis B Immune Globulin (Human) administration.

HyperHEP B S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

GamaSTAN S/D IMPORTANT SAFETY INFORMATION

GamaSTAN S/D should not be given to persons with isolated immunoglobulin A (IgA) deficiency. Such persons have the potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

GamaSTAN S/D should not be administered to patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.

GamaSTAN S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

Local pain and tenderness at the injection site, urticaria, and angioedema may occur. Anaphylactic reactions, although rare, have been reported following the injection of human immunoglobulin preparations. Anaphylaxis is more likely to occur if GamaSTAN S/D is given intravenously; therefore, GamaSTAN S/D must be administered only intramuscularly.

Administration of live virus vaccines (eg, MMR) should be deferred until approximately 3 months after Immune Globulin (Human) administration.

GamaSTAN S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.